Championing the diagnosis, prevention, and treatment 
of fungal infections for doctors, patients, and care givers
.

NIAD MSG PUBLICATIONS

Revised April 10, 2014

ORIGINAL ARTICLES, REVIEWS, BOOK CHAPTERS, EDITORIALS, ETC. SPONSORED ALL OR IN PART BY NIAID CONTRACTS

#N01-AI 82570, #N01-AI-52562, #N01-AI-15082,

 #N01-AI-65296, and NO1-AI-15440

Bolded publications indicate direct relationship to MSG clinical trial.

1980

  1. Stevens DA. Immunology of coccidioidomycosis. In: Stevens DA, ed.  Greenough WB III, Merigan TC, series eds. Coccidioidomycosis – A Text. New York: Plenum Medical Book Company, 1980:87-95.
  2. Dismukes WE, Bennett JE, Drutz DJ, Graybill JR, Remington JS, Stevens DA. Criteria for evaluation of therapeutic response to antifungal drugs. Rev Infect Dis 1980;2:535-544.
  3. Catanzaro A, Drutz DJ. Primary coccidioidomycosis. In: Stevens DA, ed.  Greenough WB III, Merigan TC, series eds. Coccidioidomycosis – A Text. New York: Plenum Medical Book Company, 1980:139-145.
  4. Catanzaro A, Drutz DJ. Pulmonary coccidioidomycosis. In: Stevens DA, ed. Greenough WB III, Merigan TC, series eds. Coccidioidomycosis – A Text. New York: Plenum Medical Book Company, 1980:147-161.
  5. Galgiani JN.  Ophthalmic coccidioidomycosis. In: Stevens DA, ed.  Greenough WB III, Merigan TC, series eds. Coccidioidomycosis – A Text.  New York: Plenum Medical Book Company, 1980:231-236.
  6. Stevens DA. Other coccidioidal syndromes. In: Stevens DA, ed. Greenough WB III, Merigan TC, series eds. Coccidioidomycosis – A Text.  New York:  Plenum Medical Book Company, 1980:237-239.
  7. Stevens DA. Coccidioidomycosis in immunocompromised hosts. In: Stevens DA, ed. Greenough WB III, Merigan TC, series eds. Coccidioidomycosis – A Text. New   York: Plenum Medical Book Company, 1980:249-252.
  8. Stevens DA. Chemotherapy of coccidioidomycosis. In: Stevens DA, ed. Greenough WB III, Merigan TC, series eds. Coccidioidomycosis -A Text. New   York: Plenum Medical Book Company, 1980:253-260.
  9. Stevens DA. Immunotherapy – transfer factor in coccidioidomycosis. In: Stevens DA, ed. Greenough WB III, Merigan TC, series eds. Coccidioidomycosis – A Text. New   York: Plenum Medical Book Company, 1980:261-268.
  10. Stevens DA. Vaccination – immunoprophylaxis in coccidioidomycosis. In: Stevens DA, ed. Greenough WB III, Merigan TC, series eds. Coccidioidomycosis – A Text. New York: Plenum Medical Book Company, 1980:269-272.
  11. Stevens DA. Bibliography of coccidioidomycosis. In: Stevens DA, ed. Greenough WB III, Merigan TC, series eds. Coccidioidomycosis – A Text. New   York: Plenum Medical Book Company, 1980:273-275.

 

1982

  1. Fromtling RA, Shadomy S, Shadomy HJ, Dismukes WE, and the NIH-NIAID Mycoses Study Group. Serotype b/c Cryptococcus neoformans isolated from patients in nonendemic areas. J Clin Micro 1982;16:408-410.

1983

  1. Dismukes WE, Stamm A, Graybill JR, Craven PC, Stevens DA, Stiller RL, Sarosi GA, Medoff G, Gregg CR, Gallis HA, Fields BT Jr, Marier RL, Kerkering TA, Kaplowitz LG, Cloud GA, Bowles C, Shadomy S. Treatment of systemic mycoses with ketoconazole: emphasis on toxicity and clinical response in 52 patients. Ann Intern Med 1983;98:13-20.
  2. Craven PC, Graybill JR, Jorgensen JH, Dismukes WE, and Levine BE. High dose ketoconazole for the treatment of fungal infections of the central nervous system. Ann Intern Med 1983;98:160-167.
  3. Stamm AM, and Dismukes WE. Cryptococcus neoformans. In: Stein JH, ed. Internal Medicine. Boston: Little Brown and Co, 1983:1439-1442.
  4. Stamm AM and Dismukes WE. Current therapy of pulmonary and disseminated fungal diseases. Chest 1983;83:911-917.

1984

  1. Pont A, Graybill JR, Craven PC, Galgiani JN, Dismukes WE, Reitz RE, and Stevens DA. High-dose ketoconazole therapy and adrenal and testicular function in humans. Arch Intern Med 1984;144:2150-2153.
  2. Bonner JR, Alexander WJ, Dismukes WE, App W, Griffin FM, Little R, and Shin MS. Disseminated histoplasmosis in patients with the acquired immune deficiency syndrome. Arch Intern Med 1984;144:2178-2181.
  3. Chapman SW. Blastomyces dermatitidis. In: Mandell GL, Douglas RG, Bennett JE, eds. Principles and Practice of Infectious Diseases. 2nd ed.   New York: John Wiley and Sons, 1984:1477-1485.

1985

  1. Shadomy S, White SC, Yu HP, Dismukes WE, and the NIAID Mycoses Study Group. Treatment of systemic mycoses with ketoconazole: in vitro susceptibilities of clinical isolates of systemic and pathogenic fungi to ketoconazole. J Infect Dis 1985;152:1249-1256.
  2. Graybill JR, Galgiani J, Stevens DA, Dismukes WE, Cloud G, Sugar A, Alsip S, Craven P, Huppert M, Bowles C, and the NIAID Mycoses Study Group. Comparison of two doses of ketoconazole in treatment of coccidioidomycosis: preliminary report. In: Einstein HE, Catanzaro A, eds. Proceedings of the 4th International Conference on Coccidioidomycosis.  Washington, DC: National Foundation for Infectious Diseases, 1985;474-482.
  3. National Institute of Allergy and Infectious Diseases Mycoses Study Group.  Treatment of blastomycosis and histoplasmosis with ketoconazole: results of a prospective randomized clinical trial.  Ann Intern Med 1985;103:861-872.

1986

  1. Alsip SG, StammAS, and Dismukes WE. Ketoconazole, miconazole and other imidazoles. In: SarosiGA, Davies SF, eds. Fungal Diseases of the Lung. Orlando: Grune & Stratton Inc, 1986:335-376.
  2. Shadomy S, Espinel-Ingroff A, Tartaglione TA, Dismukes WE, and the NIAID Mycoses Study Group. Treatment of systemic mycoses with ketoconazole: studies of ketoconazole serum levels. Mykosen 1986;29:195-209.
  3. Alsip SG, Dismukes WE. Approach to the patient with suspected histoplasmosis. In: Remington JS, SwartzMN, eds. Current Clinical Topics in Infectious Diseases. 7th ed. New York: McGraw-Hill, 1986:254-296.
  4. Dismukes WE. Blastomycosis – leave it to beaver [editorial]. N Engl J Med 1986;314:575-577.
  5. Graybill JN, Galgiani J, Stevens D, Dismukes W, Cloud G, and the NIAID Mycoses Study Group. Progress in treatment of systemic mycoses: recent trials of the Mycoses Study Group. In: Iwata K, van den Bossche H, eds. In Vitro and In Vivo Evaluation of Antifungal Agents. Elsevier Science Publishers BV, 1986:247-257.
  6. Graybill JR, Stevens D, Galgiani J, Dismukes W, and the NIAID Mycoses Study Group. Recent developments in treatment of fungal meningitis. In: Iwata K, Vanden Bossche H, eds. In vitro and In Vivo Evaluation of Antifungal Agents. Elsevier Science Publishers BV, 1986:259-270.

1987

  1. Stamm AM, and Dismukes WE. Cryptococcus neoformans. In: Stein JH, ed. Internal Medicine. 2nd ed. Boston: Little Brown and Co, 1987:1768-1772.30.
  2. Dismukes WE. Fungal endocarditis. In: Feigin RD, Cherry JC, eds. Textbook of Pediatric Infectious Diseases. 2nd ed. Philadelphia: WB Saunders Co, 1987:376-380.
  3. Carter RR, Wilson JP, Turner HR, Chapman SW.  Cutaneous blastomycosis as a complication of transthoracic needle aspiration. Chest 1987;91:917-918.
  4. Stamm AM, Diasio RB, Dismukes WE, Shadomy S, Cloud GA, Bowles CA, Karam GH, Espinel-Ingroff A, and the NIAID Mycoses Study Group.  Toxicity of amphotericin B plus flucytosine in 194 patients with cryptococcal meningitis. Am J Med 1987;83:236-242.
  5. Dismukes WE, Cloud G, Gallis HA, Kerkering TM, Medoff G, Craven PC, Kaplowitz LG, Fisher JF, Gregg CR, Bowles CA, Shadomy S, Stamm AM, Diasio RB, Kaufman L, Soong S, Blackwelder WC, and the NIAID Mycoses Study Group. Treatment of cryptococcal meningitis with combination amphotericin B and flucytosine for four as compared with six weeks.  N Engl J Med 1987;317:334-341.
  6. Shadomy HJ, Wood-Helie S, Shadomy S, Dismukes WE, Chau RY, and the NIAID Mycoses Study Group. Biochemical serogrouping of clinical isolates of cryptococcus neoformans. Diag Microbial Infect Dis 1987;6:131-138.
  7. Sugar AM, Alsip SG, Galgiani JN, Graybill JR, Dismukes WE, Cloud GA, Craven PC, Stevens DA, and the NIAID Mycoses Study Group Pharmacology and toxicity of high dose ketoconazole. Antimicrob Agents Chemother 1987;31:1874-1878.

1988

  1. Saag MS, Dismukes WE. Cryptococcosis. In: Hurst JW, ed. Medicine for the Practicing Physician. 2nd ed. Stoneham, MA: Butterworths, 1988:368-370.
  2. Saag MS, Dismukes WE. Histoplasmosis. In: Hurst JW, ed. Medicine for the Practicing Physician. 2nd ed. Stoneham, MA:  Butterworths, 1988:370-373.
  3. Saag MS, Dismukes WE. Coccidioidomycosis. In: Hurst JW, ed. Medicine for the Practicing Physician. 2nd ed. Stoneham, MA: Butterworths, 1988:375-377.
  4. Saag MS, Dismukes WE. Blastomycosis. In: Hurst JW, ed. Medicine for the Practicing Physician. 2nd ed. Stoneham, MA: Butterworths, 1988:373-375.
  5. Galgiani JN, Stevens DA, Graybill JR, Dismukes W, Cloud G, and others in the NIAID Mycoses Study Group. Ketoconazole therapy of progressive coccidioidomycosis: comparison of 400 and 800mg doses and observations at higher doses. Am J Med 1988;84:603-610.
  6. Saag MS, Dismukes WE. Azole antifungal agents: emphasis on triazoles. Antimicrob Agents Chemother 1988;32:1-8.
  7. Saag MS, Dismukes WE. Treatment of histoplasmosis and blastomycosis.  Chest 1988;93:848-851.
  8. Sarosi GA, Bates JH, Bradsher R, Davies SF, Dismukes WE, George RB, and Graybill JR. Chemotherapy of the pulmonary mycoses. Official Statement of the American Thoracic Society. Am Rev Respir Dis 1988;138:1078-1081.
  9. Dismukes WE. Cryptococcal meningitis in patients with AIDS. J Infect Dis 1988;157:624-628.
  10. Dismukes WE, Cloud GA, and the NIAID Mycoses Study Group. Treatment of cryptococcal meningitis [letter]. N Engl J Med 1988;318:380-381.
  11. Dismukes WE. Azole antifungal drugs: old and new [editorial].  Ann Intern Med 1988;109:177-179.
  12. Graybill JR, Stevens DA, Galgiani JN, Sugar AM, Craven PC, Gregg C, Huppert M, Cloud G, Dismukes WE, and the NIAID Mycoses Study Group.  Ketoconazole treatment of coccidioidal meningitis. Ann New York Acad Sci, 1988;544:488-496.
  13. Noel SB, Greer DL, Abadie SM, Zachary JA, Pankey GA. Primary cutaneous phaeohyphomycosis – a report of three cases. J Ann Acad Dermatol 1988;18:1023-1030.

1989

  1. Graybill JR. Azole Therapy of Systemic Fungal Infections. In: Holmberg K, Meyer R, eds. Diagnosis And Therapy of Systemic Fungal Infections. New York: Raven Press, 1989:133-143.
  2. Denning DW, Tucker RM, Hanson LH, Stevens DA. Itraconazole therapy of fungal infections: endemic and opportunistic mycoses. In: Holmberg K, Meyer R, eds. Diagnosis and Therapy of Systemic Fungal Infections. New York: Raven Press, 1989:145-148.
  3. Threlkeld MG, Dismukes WE. Endemic mycoses. In: Leoung GS, Mills J, eds. Opportunistic Infections in the AIDS Patient. New York: Marcel Dekker Inc, 1989:285-314.
  4. Dismukes WE. Combination therapy with amphotericin B and flucytosine for selected systemic mycoses. In: Holmberg K, Meyer RD, eds. Diagnosis and Therapy of Systemic Fungal Infections. New York: Raven Press, 1989:121-131.
  5. Johnson PC, Hamill RJ, Sarosi GA. Clinical review: progressive disseminated histoplasmosis in the AIDS patient. Seminars in Respir Infect  1989;4:139-146.

1990

  1. Chapman SW. Blastomyces dermatitidis. In: Mandell GL, Douglas RG, Bennett JE, eds. Principles and Practice of Infectious Diseases. 3rd ed.   New York: John Wiley and Sons, 1990:1999-2008.
  2. Lin AC, Goldwasser E, Bernard E, Chapman SW. Amphotericin B blunts the erythropoietin response to anemia. J Infect Dis 1990;161:348-351.
  3. Cleary JD, Taylor JW, Chapman SW. The imidazoles and triazoles in antifungal therapy. Drug Intelligence and Clinical Pharmacology, The Annals of Pharmacotherapy, 1990;24:148-152.
  4. Graybill JR, Stevens DA, Galgiani JN, Dismukes WE, Cloud GA, and the NIAID Mycoses Study Group. Itraconazole treatment of coccidioidomycosis.  Am J Med 1990;89:282-290.
  5. Fish DG, Ampel NM, Galgiani JN, Dols CL, Kelly PC, Johnson CH, Pappagianis D, Edwards JE, Wasserman RB, Clark RJ, Antoniskis D, Larsen RA, Englender SJ, Peterson EA. Coccidioidomycosis during human immunodeficiency virus infection: A retrospective review of 77 patients.  Medicine (Baltimore) 1990;69:384-391.
  6. Kramer MR, Marshall SE, Denning DW, Keogh AM, Tucker RM, Galgiani JN, Lewiston NP, Starnes VA, Stevens DA, Theodore J.  Cyclosporine and itraconazole interaction in heart and lung transplant recipients.  Ann Intern Med 1990;113:327-329.
  7. Sharkey PK, Graybill JR, Rinaldi MG, Stevens DA, Tucker RM, Peterie JD, Hoeprich PD, Greer DL, Frenkel L, Counts GW, Goodrich J, Zellner S, Bradsher RW, van der Horst CM, Israel K, Pankey GA, Barranco CP. Itraconazole treatment of phaeohyphomycosis. J Am Acad Dermatol 1990;23:577-586.

1991

  1. Dismukes WE. Epidemiology of opportunistic systemic mycoses. Current Medical Research and Opinion 1991;12 suppl 1:1-14.
  2. Dismukes WE, The present status of antifungal treatment, with particular reference to systemic infections: a review. Current Medical Research and Opinion 1991;12 suppl 1:49-59.
  3. Johnson PJ, Sarosi G. Current therapy of major fungal diseases of the lung.  Infectious Disease Clinics of North America, 1991;5 (3):635-645.
  4. Denning DW, Follansbee S, Scolaro M, Norris S, Edelstein D, and Stevens DA. Pulmonary aspergillosis in the acquired immunodeficiency syndrome. N Engl J Med, 1991;324:654-662.
  5. Stevens DA, Denning DW. Pulmonary aspergillosis in AIDS (letter). N Engl J Med 1991;325:355-357.
  6. Kramer MR, Denning DW, Marshall SE, Ross DJ, Berry G, Lewiston JN, Stevens DA, Theodore J. Ulcerative tracheobronchitis following lung transplantation: a new form of invasive aspergillosis. Amer Rev Resp Dis 1991;144:552-556.
  7. KauffmanCA, Bradley SF, Ross SC, and Wever DR:  Hepatosplenic candidiasis:  Successful treatment with fluconazole.  Am J Med 1991; 91:137-141.

1992

  1. Carr M, Dismukes WE. Antifungal drugs. In: Gorbach SL, Bartlett JG, Blacklow NR, eds. Infectious Diseases in Medicine and Surgery. Philadelphia: WB Saunders Co, 1992:306-313.
  2. Cleary JD, Taylor JW, Chapman SW. Itraconazole in antifungal therapy. Ann Pharmacother 1992;26:502-509.
  3. Stevens DA. Historical perspectives and state-of-the-art treatment of systemic mycoses compared to newer problems in management of fungal infections in debilitated and immunosuppressed hosts. In: Yamaguchi H, KobayashiGA, Talahashi H, eds. Recent Progress in Antifungal   Chemotherapy. New York: Marcel Dekker, 1992:215-226.
  4. Perfect JR. Cilofungin. In: Yamguchi H, KobayashiGA, Talahashi H, eds. Recent progress in Antifungal Chemotherapy. New York: Marcel Dekker, 1992:335-367.
  5. Perfect JR, Wright KA, Hector RF. Synergistic interaction of nikkomycin and cilofungin against diverse fungi. In: Yamguchi H, KobayashiGA, Talahashi H, eds. Recent Progress in Antifungal Chemotherapy. New York: Marcel Dekker, 1992:369-379.
  6. Medoff G, Dismukes WE, Pappagianis D, Diamond R, Gallis HA, Drutz D. Evaluation of new antifungal drugs for the treatment of systemic fungal infections. Clin Infect Dis 1992;15:S274-S281.
  7. Dismukes WE. The mycoses – an introduction.  In: Wyngaarden JB, Smith LH, Jr, Bennett JC, eds. Cecil Textbook of Medicine. 19th ed. Philadelphia:  WB Saunders Co, 1992:1886-1887.
  8. Dismukes WE. Blastomycosis. In: Wyngaarden JB, Smith LH, Jr, Bennett JC, eds. Cecil Textbook of Medicine. 19th ed. Philadelphia: WB Saunders Co, 1992:1892-1893.
  9. Dismukes WE. Candidiasis. In: Wyngaarden JB, Smith LH, Jr., and Bennett JC, eds. Cecil Textbook of Medicine. 19th ed. Philadelphia: WB Saunders Co, 1992:1898-1901.
  10. Dismukes WE. Cryptococcosis. In: Wyngaarden JB, Smith LH, Jr, and Bennett JC, eds. Cecil Textbook of Medicine. 19th ed. Philadelphia:  Saunders Co, 1992:1894-1897.
  11. Dismukes WE. Histoplasmosis. In: Wyngaarden JB, Smith LH, Jr, and Bennett JC, eds. Cecil Textbook of Medicine. 19th ed. Philadelphia: WB Saunders Co, 1992:1887-1890.
  12. Dismukes WE. Sporotrichosis. In: Wyngaarden JB, Smith LH, Jr, and Bennett JC, eds. Cecil Textbook of Medicine. 19th ed. Philadelphia: WB Saunders Co, 1992:1897-1898.
  13. Dismukes WE. Paracoccidioidomycosis. In: Wyngaarden JB, Smith LH, Jr, and Bennett JC, eds. Cecil Textbook of Medicine. 19th ed. Philadelphia:  WB Saunders Co, 1992:1893-1894.
  14. Stevens DA. Aspergillosis. In: Wyngaarden JB, Smith LH, Jr, and Bennett JC, eds. Cecil Textbook of Medicine. 19th ed. Philadelphia: WB Saunders Co, 1992:1901-1903.
  15. Chun SFS and Stevens DA. Zygomycosis (Mucormycosis). In: Wyngaarden JB, Smith LH, Jr, and Bennett JC, eds. Cecil Textbook of Medicine. 19th ed. Philadelphia: WB Saunders Co, 1992:1903-1905.
  16. Galgiani JN. Coccidioidomycosis. In: Wyngarden JB, Smith LH, Jr, and Bennett JC, eds. Cecil Textbook of Medicine. 19th ed. Philadelphia: WB Saunders Co, 1992:1890-1892.
  17. Saag MS. Dematiaceous fungal infections. In: Wyngaarden JB, Smith LH, Jr, and Bennett JC, eds. Cecil Textbook of Medicine. 19th ed. Philadelphia:  WB Saunders Co, 1992:1906-1907.
  18. Saag MS. Mycetoma. In: Wyngaarden JB, Smith LH, Jr, and Bennett JC, eds. Cecil Textbook of Medicine. 19th ed. Philadelphia: WB Saunders Co, 1992:1905-1906.
  19. Saag MS, Dismukes WE. Cryptococcosis. In: Hurst JW, ed. Medicine for the Practicing Physician. 3rd ed. Stoneham, MA: Butterworths, 1992:415-418.
  20. Saag MS, Dismukes WE. Histoplasmosis. In: Hurst JW, ed. Medicine for the Practicing Physician. 3rd ed. Stoneham, MA: Butterworths, 1992:418-420.
  21. Saag MS, Dismukes WE. Blastomycosis. In: Hurst JW, ed. Medicine for the Practicing Physician. 3rd ed. Stoneham, MA: Butterworths, 1992:420-422.
  22. Saag MS, Dismukes WE. Coccidioidomycosis. In: Hurst JW, ed. Medicine for the Practicing Physician. 3rd ed. Stoneham, MA:  Butterworths, 1992:423-425.
  23. Dismukes WE. Treatment of systemic fungal diseases in patients with AIDS.  In: Yamguchi H, KobayashiGA, Talahashi H, eds. Recent Progress in Antifungal Chemotherapy. New   York: Marcel Dekker, 1992:227-238.
  24. Saag MS, Powderly WG, Cloud GA, Robinson P, Grieco MH, Sharkey PK, Thompson SE, Sugar AM, Tuazon CU, Fisher JF, Hyslop N, Jacobson JM, Hafner R, Dismukes WE, and the NIAID Mycoses Study Group and the AIDS Clinical Trials Group. Comparison of amphotericin B with fluconazole in the treatment of acute AIDS-associated cryptococcal meningitis. N Engl J Med 1992;326:83-89.
  25. Powderly WG, Saag MS, Cloud GA, Robinson P, Meyer RD, Jacobson JM, Graybill JR, Sugar AM, McAuliffe VJ, Follansbee SE, Tuazon CU, Stern JJ, Feinberg J, Hafner R, Dismukes WE, and the NIAID AIDS Clinical Trials Group and the NIAID Mycoses Study Group.  A controlled trial of fluconazole or amphotericin B to prevent relapse of cryptococcal meningitis in patients with the acquired immunodeficiency syndrome. N Engl J Med 1992;326:793-798.
  26. Tucker RM, Denning DW, Hanson LH, Rinaldi MG, Graybill JR, Sharkey PK, Pappagianis D, Stevens DA. Interaction of azoles with rifampin, phenytoin and carbamazepine: in vitro and clinical observations. Clin Infect Dis 1992;14:165-174.
  27. Pappas PG, Pottage FC, Powderly WG, Fraser VJ, Stratton CW, McKenzie S, Tapper ML, Chmel H, Bonebrake FC, Blum R, Shafer RW, King C, and Dismukes WE. Blastomycosis in patients with the acquired immunodeficiency syndrome. Ann Intern Med 1992;116:847-853.
  28. Dismukes WE, Bradsher RW, Cloud GC, Kauffman CA, Chapman SW, George RB, Stevens DA, Girard WM, Saag MS, Bowles-Patton C, and others in the NIAID Mycoses Study Group. Itraconazole therapy of blastomycosis and histoplasmosis. Am J Med 1992;93:489-497.
  29. Dismukes WE. Antifungal therapy – from amphotericin B to present. In: Transactions of American Clinical and Climatological Association.  Williamsburg, VA: Waverly Press, 1992:166-179.
  30. Stevens DA.  Discussion of paper presented by GT Cole (targeting morphogenetic events in the parasitic cycle of Coccidioides immitis.  In: Bennett JE, Hay RJ, Peterson PK, eds. New Strategies in Fungal Disease.  Edinburgh: Churchill Livingstone, 1992:96-97.
  31. Crump JRC, Elner SG, Elner VM, and KauffmanCA:  Cryptococcal endophthalmitis:  A case report and review of the literature.  Rev Infect Dis 1992;14:1069-1073.
  32. KauffmanCA and Bagnasco FA:  Digoxin toxicity associated with itraconazole therapy.  Clin Infect Dis 1992;15:886-887.
  33. KauffmanCA:  Use of the new oral azole antifungal drugs.  Infect in Med 1992; 9:13-18.
  34. Ampel NM, Bejarano GC, Salas SD and Galgiani JN.  In vitro assessment of cellular immunity in human coccidioidomycosis: relationship between dermal hypersensitivity, lymphocyte transformation, and lymphokine production by peripheral blood mononuclear cells from healthy adults.  J Infect Dis 1992;165:710-715.

1993

  1. Sharkey PK, Kauffman CA, Graybill JR, Stevens DA, Hostetler JS, Dismukes WE and the NIAID Mycoses Study Group. Treatment of sporotrichosis with itraconazole. Am J Med 1993;95:279-285.
  2. Wheat J, Hafner J, Wulfsohn M, Spencer P, Squires K, Powderly W, Wong B, Rinaldi M, Saag M, Hamill R, Murphy R, Connolly-Stringfield P, Briggs N, Owens S, Johnson J, Relue J, Lengendre R, and the NIAID AIDS Clinical Trials Group and Mycoses Study Group collaborators.  Prevention of relapse of  histoplasmosis with itraconazole in patients with the acquired immunodeficiency syndrome.   Ann Intern Med 1993;118:610-616.
  3. KemperCA, Hostetler JS, Follansbee SE, Ruane P, Covington DD, Leong SS. Deresinski SC, and Stevens DA. Ulcerative and plaque-like tracheobronchitis due to infection with Aspergillus in patients with HIV infection. Clin Infect Dis 1993;17:344-352.
  4. Rex JH, Larsen RA, Dismukes WE, Cloud GA, Bennett JE. Catastrophic visual loss due to Cryptococcus neoformans meningitis. Medicine 1993;72:207-224.
  5. Dismukes WE. Management of cryptococcosis. Clin Infect Dis 1993;17:S502-512.
  6. Galgiani JN, Catanzaro A, Cloud GA, Higgs J, Friedman BA, Larsen RA, Graybill JR, and the NIAID Mycoses Study Group. Fluconazole therapy for coccidioidal meningitis. Ann Intern Med 1993;119:28-35.
  7. Ampel NA, Dols CL, Galgiani JN. Coccidioidomycosis during human immunodeficiency virus infection: results of a prospective study in a coccidioidal endemic area. Am J Med 1993;94:235-240.
  8. Johnson PC, Sarosi GA. Progressive disseminated histoplasmosis in HIV-infected patients. In: SarosiGA, Davies SF, eds. Fungal Diseases of the Lung. New York: Raven Press, 1993:247-255.
  9. Pappas PG, Threlkeld MG, Bedsole GD, Cleveland KO, Gelfand MS, Dismukes WE. Blastomycosis in immunocompromised patients. Medicine 1993;72:311-325.
  10. Peng T, Galgiani JN. In vitro studies of a new antifungal triazole, D0870, against Candida albicans, Cryptococcus neoformans, and other pathogenic yeasts.  Antimicrob Agents Chemother 1993;37:2126-2131.
  11. Kauffman CA Bradley SF, and VineAK:  Candida endophthalmitis associated with intraocular lens implantation.  Efficacy of fluconazole therapy.  Mycoses 1993;36:13-17.

 1994

  1. Denning DW, Lee JY, Hostetler JS, Pappas P, Kauffman CA, Dewsnup DH, Galgiani JN, Graybill JR, Sugar AM, Catanzaro A, Gallis H, Perfect JR, Dockery B, Dismukes WE, Stevens DA. NIAID Mycoses Study Group multicenter trial of oral itraconazole therapy for invasive aspergillosis.  Am J Med 1994;97:135-144.
  2. Hostetler JS, Catanzaro A, Stevens DA, Graybill JR, Sharkey PK, Larsen RA, Tucker RM, Al-Haidary AD, Rinaldi MG, Cloud GA, Galgiani JN.  Treatment of coccidioidomycosis with SCH 39304.  J Med Vet Mycology 1994;32:105-114.
  3. Como JA, Dismukes WE. Systemic antifungal therapy: focus on oral azole drugs. N Engl J Med 1994;330:263-272.
  4. Powderly WG, Cloud GA, Dismukes, WE, Saag MS. Measurement of cryptococcal antigen in serum and cerebrospinal fluid: value in the management of AIDS associated cryptococcal meningitis. Clin Infect Dis 1994;18:789-92.
  5. Lopez R, Mason JO, Parker JS, Pappas PG. Intraocular blastomycosis:  case report and review. Clin Infect Dis 1994;18:805-807.
  6. Sangeorzan JA, Bradley SF, He X, Zarins LT, Ridenour GL, Tiballi RN, Kauffman CA.  Epidemiology of oral candidiasis in HIV-Infected patients:  colonization, infection, treatment, and emergence of fluconazole resistance.  Am J Med 1994;97:339-346.
  7. Rex JH, Bennett JE, Sugar AM, Pappas PG, van der Horst CM, Edwards JE, Washburn RG, Scheld WM, Karchmer AW, Dine AP, Levenstein MJ, Webb CD, for the Candidemia Study Group and the NIAID Mycoses Study Group. A randomized trial comparing fluconazole with amphotericin B for the treatment of candidemia in patients without neutropenia.  N Engl J Med 1994;331:1325-1330.
  8. Kauffman CA:  New developments in therapy for endemic mycoses.  Clin Infect Dis  1994;19:S28-S36.
  9. Voice RA, Bradley SF, Sangeorzan JA, and KauffmanCA:  Chronic Candida meningitis.  An uncommon manifestation of candidiasis.  Clin Infect Dis 1994;19: 60-66.
  10. He X, Tiballi RN, Zarins LT, Bradley SF, Sangeorzan JA, and KauffmanCA:  Azole resistance in oropharyngeal Candida albicans strains isolated from patients with HIV infection.  Antimicrob Agents Chemother 1994;38:2495-2497.
  11. Villareal KM, Cook RA, Galgiani JN, Wenzel RP, Pappas PG, Pottage JC Jr, Gallis HA, Crane, LR.  Comparative analysis of three antifungal susceptibility test methods against prospectively collected Candida species.  Diagn Microbial Infect Dis 1994;18:89-94.
  12. Stevens DA.  Management of systemic fungal disease in AIDS patients.  J Am Acad Derm 1994;31:S64-S67.
  13. Denning DW, AmpelNM, Stevens DA.  Opportunistic mycoses in HIV infection: aspergillosis and coccidioidomycosis.  HIV Advances in Research and Therapy 1994;4:22-29.
  14. Stevens DA.  Overview of amphotericin B colloidal dispersion (Amphocil).  J. Infection 1994;28(1)45-49.
  15. Dewsnup DH, Stevens DA.  Efficacy of oral amphotericin B in AIDS patients with thrush clinically resistant to fluconazole.   J Med Vet Mycol 1994;32:389-393.
  16. KauffmanCA.  Blastomycosis.  In: Conn’s Current Therapy.  Rakel RE (ed).  W.B. Saunders Co, Philadelphia, PA 1994;176-178.
  17. Cadle RN, Zenon III GJ, Rodriquez-Barradas MC and Hamill RJ.  Fluconazole-induced symptomatic phenytoin toxicity.  Ann Pharmacother 1994;28:191-195.

1995

  1. Pappas PG, Bradsher RW, Chapman SW, Kauffman CA, Dine A, Cloud GA, Dismukes WE, and the NIAID Mycoses Study Group. Treatment of blastomycosis with  fluconazole. Clin Infect Dis 1995;20:267-71.
  2. Catanzaro A, Galgiani JN, Levine BE, Sharkey-Mathis PK, Fierer J, Stevens DA, Chapman SW, Cloud G, and others in the NIAID Mycoses Study Group. Fluconazole in the treatment of chronic pulmonary and non-meningeal disseminated coccidioidomycosis.  Am J Med 1995;98:249-256.
  3. Johnson PC, Sarosi GA. The endemic mycoses: surgical considerations.  Seminars in Thoracic and Cardiovascular Surgery 1995; 7:95-103.
  4. Pappas PG, Kauffman CA, Perfect J, Johnson PC, McKinsey DS, Bamberger DM, Sobel JD, and others in the NIAID Mycoses Study Group.  Alopecia associated with fluconazole therapy.  Ann Intern Med 1995;123:354-7.
  5. Ampel NM, Ahmann DR, Delgado KL, Galgiani JH, Cloud GA, and the NIAID Mycoses Study Group.  Tumor necrosis factor-a and interleukin-18 in cerebrospinal fluid of patients with coccidioidal meningitis during therapy with fluconazole. J Infect Dis 1995;171:1675-8.
  6. Mangino JE, Pappas PG.  Itraconazole for the treatment of histoplasmosis and blastomycosis.  Intl J Antimicro A 1995;5:219-225.
  7. Stevens DA, Coccidioidomycosis (invited review).  N Engl J Med 1995;332:1077-1082.
  8. Spindel SJ, Hamill RJ, Georghiou PR, Lacke CE, Green LK, and Mallette LE.   Vitamin D-mediated hypercalcemia in fungal infections.  Am J Med Sci 1995;310:71-76
  9. Rex J, Pfaller MA, Barry AL, Nelson PW, Webb CD, NIAID Mycoses Study Group and the Candidemia Study Group.  Antifungal susceptibility testing of isolates from a randomized, multicenter trial of fluconazole vs. amphotericin b as treatment of non-neutropenic patients with candidemia.  Antimicrob Agents Chemother 1995;39:40-44.
  10. KauffmanCA:  Endemic mycoses in older adults.  Infect Dis Clin Prac 1995;4:41-45.
  11. Tiballi RN, He X, Zarins LT, Revankar S, and Kauffman CA:  Use of a colorimetric system for yeast susceptibility testing.  J Clin Microbiol 1995;33: 915-917.
  12. Rex JH, Bennett JE, Sugar AM, Pappas PG, Serody J, Edwards JE, and Washburn RG for the NIAID Mycoses Study Group and the Candidemia Study Group.  Intravascular catheter exchange and the duration of candidemia.  Clin Infect Dis 1995;21:944-6.
  13. Lutz JE, Stevens DA.  Treatment of invasive aspergillosis.  Int Med 1995;16(supplement):25-31.
  14. KauffmanCA.  Antifungal prophylaxis – effectiveness in the immunocompromised host.  Mycology 1995:60-64.
  15. KauffmanCA.  Oral antifungal agents in office practice.  Clin Updates in Fungal Infections 1995;1(2):1-4.
  16. Tiballi RN, Zarins LT, Xiaogang HE, KauffmanCA.  Torulopsis glabrata: Azole susceptibilities by microdilution colorimetric and macrodilution broth assays.  J Clin Micro 1995;33:2612-2615.
  17. Kauffman CA.  Old and new therapies for sporotrichosis. Clin Infect Dis 1995;21:981-985.

1996

  1. Kauffman CA, Pappas PG, McKinsey DS, Greenfield RA, Perfect JR, Cloud GA, Thomas CJ, Dismukes WE and NIAID Mycoses Study Group.  Treatment of lymphocutaneous and visceral sporotrichosis with fluconazole. Clin Infect Dis 1996;22:44-50.
  2. Dewsnup DH, Galgiani JN, Graybill JR, Diaz M, Rendon A, Cloud GA, Stevens, DA.  Is it ever safe to stop azole therapy for Coccidioides immitis meningitis? Ann Intern Med. 1996;124:305-310.
  3. Dismukes WE.   Introduction to the Mycoses.  In: Bennett JC, Plum F, eds. Cecil Textbook of Medicine. 20th ed. Philadelphia: WB Saunders.  1996:1815-1816.
  4. Dismukes WE.  Histoplasmosis. In:  Bennett JC, Plum F, eds. Cecil Textbook of Medicine. 20th ed. Philadelphia: WB Saunders.  1996:1816-1819.
  5. Galgiani JN.  Coccidioidomycosis. In:  Bennett JC, Plum F, eds. Cecil Textbook of Medicine. 20th ed. Philadelphia: WB Saunders.  1996:1819-1820.
  6. Dismukes WE.  Blastomycosis. In:  Bennett JC, Plum F, eds. Cecil Textbook of Medicine. 20th ed. Philadelphia: WB Saunders.  1996:1821-1822.
  7. Dismukes WE.  Paracoccidioidomycosis.   In:  Bennett JC, Plum F, eds. Cecil Textbook of Medicine. 20th ed. Philadelphia: WB Saunders.   1996:1822-1823.
  8. Dismukes WE.  Cryptococcosis. In:  Bennett JC, Plum F, eds. Cecil Textbook of Medicine. 20th ed. Philadelphia: WB Saunders.  1996:1823-1826.
  9. Dismukes WE.  Sporotrichosis. In:  Bennett JC, Plum F, eds. Cecil Textbook of Medicine. 20th ed. Philadelphia: WB Saunders.  1996:1826-1827.
  10. Dismukes WE.  Candidiasis. In:  Bennett JC, Plum F, eds. Cecil Textbook of Medicine. 20th ed. Philadelphia: WB Saunders.  1996:1827-1830.
  11. Stevens DA.  Aspergillosis.  In:  Bennett JC, Plum F, eds. Cecil Textbook of Medicine. 20th ed. Philadelphia: WB Saunders.  1996:1830-1832.
  12. Chun S, Stevens DA. Mucormycosis. In:  Bennett JC, Plum F, eds. Cecil Textbook of Medicine. 20th ed. Philadelphia: WB Saunders.  1996:1832-1834.
  13. Saag MS.  Mycetoma. In:  Bennett JC, Plum F, eds. Cecil Textbook of Medicine. 20th ed. Philadelphia: WB Saunders.  1996:1834-1835.
  14. Saag MS.  Dematiaceous Fungal Infections. In:  Bennett JC, Plum F, eds. Cecil Textbook of Medicine. 20th ed. Philadelphia: WB Saunders.  1996:1836.
  15. Galgiani JN, Peng T, Lewis ML, Cloud GA, Pappagianis D, and the NIAID Mycoses Study Group .Cerebrospinal fluid antibodies detected by ELISA against a 33 Kda antigen from spherules of Coccidioides immitis in patients with coccidioidal meningitis.  J  Infect Dis 1996;173:499-502.
  16. Brandt ME, Hutwagner, LC, Klug LA, Baughman DR, Graviss EA, Hamill RJ, Thomas C, Pappas PG, Reingold AL, Pinner RW and the Cryptococcal Disease Active Surveillance Group. Molecular subtype distribution of Cryptococcus neoformans in four areas of the United States.  J Clin Micro 1996; 34:912-917.
  17. Ampel NE.  Emerging disease issues and fungal pathogens associated with HIV infection.  Emerging Inf Dis 1996;2:109-116.
  18. Graybill JR.  Lipid formulations for amphotericin B: Does the emperor need new clothes?  Ann Int Med 1996;124(10):921-923.
  19. Pankey GE, Greer DL.  Miscellaneous Fungi and Algae.  In: Schlossberg D, ed. Current Therapy of Infectious Disease.  St. Louis, MO: Mosby, Inc.  1996:602-604.
  20. Banuelos AF, Williams PL, Johnson RH, Bibi S, Fredricks DN, Gilroy SA, Bhatti SU, Aguet J, Stevens DA. Central nervous system abscesses due to coccidioides species.  Clin Infect Dis 1996;22:240-250.
  21. Clemons KV, Azzi R, Stevens DA.  Experimental systemic cryptococcosis in SCID mice.  J Med Vet Mycol 1996;34:331-335.
  22. Grover DD, Brummer E, Stevens DA.  Study of the role or iron in the anticryptococcal activity of human serum and fluconazole.  Mycopathologia 1996;133:71-77.
  23. KauffmanCA, Lynch JP.  Fungal Pneumonia.  In: Pulmonary and Respiratory Therapy Secrets.  Parsons PE and Heffner JE (eds).  Hanley & Belfus, Inc., Philadelphia, PA 1996:150-159.
  24. Kauffman CA.  Role of azoles in antifungal therapy.  Clin Infect Dis 1996;22(2):S148-153.
  25. McKinsey DS, Kauffman CA, Pappas PG, Cloud GA, Girard WM, Sharkey-Mathis PK, Hamill RJ, Thomas CJ, Dismukes WE and the NIAID Mycoses Study Group.  Fluconazole therapy for histoplasmosis.  Clin Infect Dis 1996;23:996-1001.
  26. Pappas PG, Dismukes WE.  Blastomycosis.   In: Schlossberg D, ed. Current Therapy of Infectious Disease.  St. Louis, MO: Mosby, Inc. 1996:598-599.
  27. Corry DB, Ampel NM, Christian L, Locksley RM and Galgiani JN.  Cytokine production by peripheral blood mononuclear cells in human coccidioidomycosis.  J Infect Dis 1996;174:440-443.

1997

  1. KauffmanCA.  Histoplasmosis.  In: Conn’s Current Therapy.  Rakel RE (ed).  W. B. Saunders Co., Philadelphia, PA 1997:200-201.
  2. Pappas PG.  Blastomycosis.  In: Conn’s Current Therapy.  Rakel RE (ed).  W. B. Saunders Co., Philadelphia, PA 1997:201-202.
  3. KauffmanCA.  Antifungal agents.  In: Infectious Disease and Antimicrobial Therapy of the Ears, Nose, and Throat.  Johnson JT and Yu VL (eds).  W.B. Saunders Co., Philadelphia, PA 1997:129-135.
  4. Kauffman CA, Carver PL.  Antifungal agents in the 1990s: current status and future developments.  Drugs 1997;53(4):539-549.
  5. Pappas PG, Bradsher RW, Kauffman CA, Cloud GA, Thomas CT, Campbell, Jr. GD, Chapman SW, Chapman SW, Newman C, Dismukes WE and the NIAID Mycoses Study Group.  Treatment of blastomycosis with higher dose fluconazole.  Clin Infect Dis 1997;25:200-205.
  6. Van der Horst CM, Saag MS, Cloud GA, Hamill RJ, Graybill JR, Sobel JD, Johnson PC, Tuazon CU, Kerkering T, Fisher JF, Henderson H, Stansell J, Mildvan D, Moskovitz BL, Powderly WG, Riser L, Thomas C, Schneider D, Hafner R, Dismukes WE, and the NIAID Mycoses Study Group and the AIDS Clinical Trials Group.  Treatment of  cryptococcal meningitis associated with the acquired immunodeficiency syndrome.  N Eng J Med 1997;337:15-21.
  7. Hamill RJ and Hollander H.  Infectious Diseases: Mycotic.  In: Tierney Jr LM, McPhee SJ and Papadakis MA, (eds).  Current Medical Diagnosis and Treatment 1997, Appleton and Lange, Stamford, CT, Infect Dis in Clin Practice 1997:1356-1367.
  8. Spindel SJ, Lacke CE, Pellegrino CR, Graviss EA and Hamill RJ.  Noncandidal fungal peritonitis in patients with AIDS: report of three cases and review.  Clin Infect Dis 1997;24:279-280.
  9. Wheat J, MaWhinney S, Hafner R, McKinsey D, Chen D, Korzun A, Shakan KJ, Johnson P, Hamill R, Bamberger D, Pappas P, Stansell J, Koletar S, Squires K, Larsen RA, Cheung T, Hyslop N, Lai KK, Schneider D, Kauffman C, Saag M, Dismukes W, Powderly W for the National Institute of Allergy and Infectious Diseases AIDS Clinical Trials Group and Mycoses Study Group.  Treatment of histoplasmosis with fluconazole in patients with acquired immunodeficiency syndrome.  Am J Med 1997;103:223-232.
  10. Stevens DA and Lee JY.  Analysis of compassionate use itraconazole therapy of invasive aspergillosis by the NIAID Mycoses Study Group criteria.  Archives Int Med 1997;157:1857-1862.
  11. McKinsey D, Spieel R, Hutwagner L, Stanford J, Driks M, Brewer J, Gupta M, Smith D, O’Conner M, Dall L.  Prospective study of histoplasmosis in patients infected with human immunodeficiency virus: incidence, risk factors, and pathophysiology.  Clin Infect Dis 1997;24:1195-1203.
  12. KauffmanCA.  Systemic fungal infections.  Chapter 11.  In: Atlas of Infectious Diseases.  Mandell GL (ed).  Current Medicine, Philadelphia, PA, 1997.
  13. KauffmanCA.  Amphotericin B.  In: Invasive Fungal Infections.  Sem Resp Crit Care Med.  Lynch JP (ed)1997;18:281-287.
  14. Edwards JE, Bodey GP, Bowden RA, Bucher T, de Pauw BE, Filler SG, Ghannoum MA, Glauser M. Herbrecht R, Kauffman CA, et al.  International conference for the development of a consensus on the management and prevention of severe candidal infections.  Clin Infect Dis 1997; 25:43-59.
  15. AmpelNM and Christian L.  In vitro modulation of proliferation and cytokine production by human peripheral blood mononuclear cells from subjects with various forms of coccidioidomycosis.  Infect and Immun 1997; 4483-4487.
  16. Byrne R, Hamill RJ and Rodriquez-Barradas MC.  Cryptococcuria: Case reports and literature review.  Infectious Disease in Clinical Practice 1997;6:513-518.
  17. Pappas PG.  Blastomycosis in immunocompromised patients.  Seminars in Respiratory Infections 1997; 12 (3):243-51.
  18. Denning DW, Venkateswarlu K, Oakley KL, Anderson MJ, ManningNJ, Stevens DA, Warnock DW and Kelly SL.  Itraconazole resistance Aspergillus fumigatus.  Antimicrobial Agents & Chemotherapy  1997; 41 (6):1364-8.
  19. Natarajan U, Randhawa N, Brummer E. and Stevens DA.  Effect of Granulocyte Macrophage-Colony Stimulating Factor (GM-CSF) on Candidacidal Activity of Neutrophils, Monocytes, or Monocyte-Derived Macrophages and Synergy with Fluconazole.  Antimicrobial Agents & Chemotherapy  1997; 41 (7):1575-1578.

1998

 

  1. McKinsey D. Community-acquired fungal pneumonias.  In: Ellis M (ed), Infectious Diseases of the respiratory tract.  Cambridge: CambridgeUniversity Press, 1998; 305-332.
  2. Thomas CJ, Lee JY, Conn LA, Bradley ME, Gillespie RW, Dill SR, Pinner RW and Pappas PG.  Surveillance of cryptococcosis in Alabama, 1992-1994.  Ann Epidemiol 1998;8:212-216.
  3. Visnegarwala F, Graviss EA, Lacke CE, Dural AT, Johnson PC, Atmar RL and Hamill RJ.  Acute respiratory failure associated with cryptococcosis in patients with AIDS: Analysis of predictive factors.  Clin Infect Dis 1998;27:1231-1237.
  4. KauffmanCA.  Sporotrichosis:  Fungal infections in immunocompromised hosts.  Focus on epidemiologic aspects of infection.  National Foundation for Infectious Diseases.  February 1998.
  5. Warnock DW, DuPont B, KauffmanCA, Sirisanthana T.  Imported mycoses in Europe.  Med Mycology 1998; 36 (Suppl 1): 87-94.
  6. McKinsey D.  Histoplasmosis in the acquired immunodeficiency syndrome: advances in management.  AID Patient Care and STDS 1998;12:775-781.

1999

  1. Saag MS, Cloud GA, Graybill JR, Sobel JD, Tuazon CU, Johnson PC, Fessel JY, Moskovitz BL, Weisinger B, Cosmatos D, Riser L, Thomas C, Hafner R, Dismukes WE, and the NIAID Mycoses Study Group.  A comparison of itraconazole versus fluconazole as maintenance therapy for AIDS-associated cryptococcal meningitis.  Clin Infect Dis 1999;28:291-296.
  2. Hajjeh RA, Conn LA, Stephens DS, Baughman W, Hamill R, Graviss E, Pappas PG, Thomas C, Reingold A, Rothrock G, Hutwagner LC, Schuchat A, Brandt ME, Pinner RW and the Cryptococcal Active Surveillance Group.  Cryptococcosis: population-based multistate active surveillance and risk factors in human immunodeficiency virus-infected persons.  J Infect Dis 1999;179:449-454.
  3. Walsh T, Feinberg R, Arndt C, Hiemenz J, Schwartz C, Bodensteiner D, Pappas P, Seibel N, Greenberg R, Dummer S, Schuster M, Holcenberg JS and the NIAID Mycoses Study Group.  Liposomal amphotericin B for empirical therapy in patients with persistent fever and neutropenia.  N Eng J Med 1999;340:764-771.
  4. Bamberger DM.  Successful treatment of multiple cerebral histoplasmosis with itraconazole.  Clin Infect Dis 1999;28:915-916.
  5. Hamill RJ.  Infectious diseases: Mycotic.  In: Tierney Jr LM, McPhee SJ and Papadakis MA, (eds).  Current Medical Diagnosis and Treatment 1999, Appleton and Lange, Stamford, CT, 1999:1418-1430.
  6. McKinsey D, Wheat J, Cloud G, Pierce M, Black J, Bamberger D, Goldman M, Thomas C, Gutsch H., Moskovitz B, Dismukes W, Kauffman C and the NIAID Mycoses Study Group.  Itraconazole prophylaxis against fungal infections in patients with advanced human immunodeficiency virus infection: randomized placebo-controlled double-blind study.  Clin Infect Dis 1999;28:1049-1056.
  7. Saag MS, Fessel WJ, Kaufman C, Merrill KW, Ward DJ, Moskovitz BL, Thomas C, Oleka N, Guarnieri JA, Lee J, Brenner-Gati L, Klausner M.  Treatment of fluconazole-refractory oropharyngeal candidiasis with itraconazole oral solution in HIV-positive patients.  AIDS Res  and Human Retroviruses 1999;15:1413-1417.
  8. Pappas PG, Edwards JE.  Antifungal Drugs.  In:  Clinical Infectious Diseases:  A Practical Approach.  Root RK  (ed.).  OxfordUniversity Press, New York, NY 1999:389-395.
  9. Pappas PG, Edwards JE.  Selection of Antifungal Drugs for Deep Mycoses. In:  Clinical Infectious Diseases:  A Practical Approach.  Root RK  (ed.). OxfordUniversity Press,New York,NY 1999; 397-404.
  10. KauffmanCA.  Sporotrichosis.  In:  Antimicrobial Therapy and Vaccines.  Yu VL, Merigan T, Barriere S (eds).  Williams & Wilkins, 1999, pp. 1137-1138.
  11. KauffmanCA.  Systemic antifungal agents:  What is in the pipeline?  Drugs in R&D 1999.
  12. KauffmanCA.  Sporotrichosis.  Clinical Infect Dis 1999; 29:231-237.
  13. KauffmanCA.  Opportunistic fungal infections:  An update on cryptococcosis.  J Crit Illness 1999; 14:129-132.
  14. KauffmanCA.  When to suspect fungal infection as the cause of non-resolving pneumonia.  J Respir Dis 1999; 20:283-293.
  15. KauffmanCA.  Recognizing histoplasmosis as a cause of pneumonia.  J Respir Dis 1999; 20:351-354.
  16. Galgiani JN.  Coccidioidomycosis: A regional disease of national importance-rethinking approaches for control.  Ann Intern Med 1999; 130:293-300.

2000

  1. Malani, PA, KauffmanCA.  Prevention and prophylaxis of invasive fungal sinusitis in the immunocompromised patient.  Fungal rhinosinusitis:  A spectrum of diseases.  Otolaryngologic Clin N Amer 2000; 33:301-312.
  2. Sobel JD, Kauffman CA, McKinsey D, Zervos M, Vazquez JA, Karchmer AW, Lee J, Thomas C.  Candiduria:  A randomized, double blind study of treatment with fluconazole and placebo.  Clin Infect Dis 2000;30:19-24.
  3. Graybill JR, Sobel J, Saag M, van der Horst C, Powderly W, Cloud G, Riser L, Hamill R, Dismukes W and the NIAID Mycoses Study Group (MSG) and AIDS Clinical Trial Group (ACTG).  Diagnosis and management of increased intracranial pressure in patients with AIDS and cryptococcal meningitis.  Clin Infect Dis 2000;30:47-54.
  4. Kauffman CA, Vazquez JA, Sobel JD, Gallis HA, McKinsey DS, Karchmer AW, Sugar AM, Sharkey PK, Wise GJ, Mangi R, Mosher A, Lee JY, Dismukes WE, and the NIAID Mycoses Study GroupProspective multicenter surveillance study of funguria in hospitalized patients. Clin Infect Dis 2000;30:14-18.
  5. Pappas PG, Tellez I, Deep AA, Nolasco D, Holgado W, Bustamante B.  Sporotrichosis in Peru: description of a area of hyperendemicity. Clin Infect Dis 2000;30:65-70.
  6. Stevens DA, Schwartz HJ, Lee JY, Moskovitz BL, Jerome DC, Catanzaro A, Bamberger DM, Weinmann AJ, Tuazon CU and DeGraff AC.  A randomized trial of itraconazole in allergic bronchopulmonary aspergillosis. N Engl J Med 2000; 342:756-763
  7. Dismukes WE.  The mycoses-introduction. In: Cecil Textbook of Medicine.  Goldman L, Bennett JC, eds. 21 ed., W.B. Saunders Co., Philadelphia, 2000:1858-1860.
  8. Dismukes WE.  Histoplasmosis. In: Cecil Textbook of Medicine.  Goldman L, Bennett JC, eds. 21 ed., W.B. Saunders Co., Philadelphia, 2000:1860-1862
  9. Galgiani JN.  Coccidioidomycosis. In: Cecil Textbook of Medicine.  Goldman L, Bennett JC, eds. 21 ed. W.B. Saunders Co., Philadelphia 2000:1863-1864
  10. Dismukes WE.  Blastomycosis. In: Cecil Textbook of Medicine.  Goldman L, Bennett JC, eds. 21 ed., W.B. Saunders Co., Philadelphia, 2000:1865-1866
  11. Dismukes WE.  Paracoccidioidomycosis. In: Cecil Textbook of Medicine.  Goldman L, Bennett JC, eds. 21 ed., W.B. Saunders Co., Philadelphia, 2000:1866-1867
  12. Dismukes WE.  Cryptococcosis. In: Cecil Textbook of Medicine.  Goldman L, Bennett JC, eds. 21 ed., W.B. Saunders Co., Philadelphia, 2000:1867-1870.
  13. Dismukes WE.  Sporotrichosis. In: Cecil Textbook of Medicine.  Goldman L, Bennett JC, eds. 21 ed., W.B. Saunders Co., Philadelphia, 2000:1870-1871.
  14. Dismukes WE.  Candidiasis. In: Cecil Textbook of Medicine.  Goldman L, Bennett JC, eds. 21 ed., W.B. Saunders Co., Philadelphia, 2000:1871-1875.
  15. Stevens DA.  Aspergillosis. In: Cecil Textbook of Medicine.  Goldman L, Bennett JC, eds. 21 ed. W.B. Saunders Co., Philadelphia 2000:1875-1877.
  16. Chun SFS, Stevens DA.  Mucormycosis.  In: Cecil Textbook of Medicine.  Goldman L, Bennett JC, eds. 21 ed. W.B. Saunders Co., Philadelphia 2000:1883-1885.
  17. Saag MS.  Mycetoma.  In: Cecil Textbook of Medicine.  Goldman L, Bennett JC, eds. 21 ed. W.B. Saunders Co., Philadelphia 2000:1885-1887.
  18. Saag MS.  Dematiaceous fungal infections.  In: Cecil Textbook of Medicine.  Goldman L, Bennett JC, eds. 21 ed. W.B. Saunders Co., Philadelphia 2000:1887-1888.
  19. Sobel JD.  Practice guidelines for the treatment of fungal infections.  Clin Infect Dis 2000;30:652.
  20. Dismukes WE.  Introduction to antifungal drugs.  Clin Infect Dis, 2000;30:653-657.
  21. Galgiani JN, AmpelNM, Catanzaro A, Johnson RH, Stevens DA, Williams PL.  Practice guidelines for the treatment of coccidioidomycosis.  Clin Infect Dis 2000;30:658-661.
  22. Rex JH, Walsh TH, Sobel JD, Filler SG, Pappas PG, Dismukes WE, Edwards JE.  Practice guidelines for the treatment of candidiasis.  Clin Infect Dis 2000;30:662-678.
  23. Chapman SW, Bradsher RW, Campbell GD, Pappas PG, Kauffman CA.  Practice guidelines for the management of patients with blastomycosis.  Clin Infect Dis 2000;30:679-683.
  24. Kauffman CA, Hajjeh R, Chapman SW.  Practice guidelines for the management of patients with sporotrichosis.  Clin Infect Dis 2000;30:684-687.
  25. Wheat J, Sarosi G, McKinsey D, Hamill R, Bradsher R, Johnson P, Loyd J, Kauffman C.  Practice guidelines for the management of patients with histoplasmosis.  Clin Infect Dis 2000;30:688-695.
  26. Stevens DA, Kan VL, Judson MA, Morrison VA, Dummer S, Denning DW, Bennett JE, Walsh TJ, Patterson TF, Pankey GA.  Practice guidelines for diseases caused by Aspergillus.  Clin Infect Dis 2000;30:696-709.
  27. Saag MS, Graybill RJ, Larsen RA, Pappas PG, Perfect JR, Powderly WG, Sobel JD, Dismukes WE.  Practice guidelines for the management of cryptococcal disease.  Clin Infect Dis 2000;30:710-718.
  28. Lutz JE, Clemons KV, Stevens DA.  Enhancement of antifungal chemotherapy by interferon-gamma in experimental systemic cryptococcosis.  Antimicrobiol Chemother. 2000;46:1-6.
  29. Galgiani JN, Catanzaro A, Cloud GA, Johnson RH, Williams PL, Mirels LF, Nassar F, Lutz J, Stevens DA, Sharkey PK, Singh VR, Larsen RA, Delgado KL, Flanigan C, Rinaldi MG and the NIAID Mycoses Study Group.  Comparison of oral fluconazole and itraconazole for progressive nonmeningeal coccidioidomycosis.  Ann Intern Med. 2000; 133:676-686.
  30. Goldman M, Cloud GA, Smedema ML, Connolly PA, McKinsey DS, Kauffman CA, Moskovitz BL, Wheat J, and the NIAID Mycoses Study Group.    Does long-term itraconazole prophylaxis result in azole resistance in mucosal Candida albicans isolates from persons with advanced HIV-infection. J Clin Micro. 2000:44; 1585-1587.
  31. Cagnoni P, Walsh TJ, Prendergast M, Arndt CAS, Bodensteiner D, Greenberg RN, Hiemenz S, Schuster M, Seibel N, Yeldandi V, Tong K.  Pharmacoeconomic analysis of liposomal amphotericin B versus conventional amphotericin B deoxycholate in the empirical treatment of persistently febrile neutropenic patient.  J Clin Oncol. 2000; 18: 2476-2483.
  32. KauffmanCA.  Histoplasmosis.  Current Treatment Options in Infectious Diseases 2. 2000:487-491.
  33. KauffmanCA.  Blastomycosis.  Current Treatment Options in Infectious Diseases 2. 2000:481-485.
  34. KauffmanCA.  Sporotrichosis.  Current Treatment Options in Infectious Diseases 2.  2000:493-497.
  35. KauffmanCA.  Sporotrichosis.  In:  Atlas of Infectious Diseases, Mandell GL (ed).  Current Medicine, Philadelphia, PA 2000:65-77.
  36. Kontoyiannis DP, Wessel VC, Bodey GP and Rolston KVI.  Zygomycosis in the 1990s in a tertiary care cancer center. Clin Inf Dis 2000; 30:851-856.

2001 

  1. Hajjeh RA, Pappas PG, Henderson H, Lancaster D, Bamberger DM, Skahan KJ, Phelan MA, Cloud G, Holloway M, Wheat LJ and the MSG Endemic Mycoses Subproject Group.  A multicenter, case-control study of risk factors for histoplasmosis in HIV-infected persons.  Clin Infect Dis. 2001:32;1215-1220.
  2. Wheat LJ, Cloud GA, Johnson PC, Connolly P, Goldman M, Monte AL, Fuller DE, Davis TE, Hafner R, The Aids Clinical Trials Group and the NIAID Mycoses Study Group.  Clearance of fungal burden during treatment of disseminated histoplasmosis with liposomal amphotericin b versus itraconazole.  Antimicrobiol Chemother 2001:45; 2354-2357.
  3. Perfect JR, Cox GM, Lee JY, Kauffman CA, de Repentigny L, Chapman SW, Morrison VA, Pappas P, Hiemenz JW, Stevens DA and the NIAID Mycoses Study Group.  The impact of culture isolation of Aspergillus species:  a hospital based survey of aspergillosis.  Clin Infect Dis. 2001; 33:1824-1833.
  4. Wheat LJ, Connolly P, Smedema M., Brezendine E, Hafner R, for the AIDS Clinical Trials Group and the Mycoses Study Group for the National Institute of Allergy and Infectious Diseases.  Emergence of resistance to fluconazole as a cause of failure during treatment of histoplasmosis in-patient with acquired Immunodeficiency Disease Syndrome. Clin Infect Dis. 2001; 33:1910-1913.
  5. LeMonte AM, Goldman M, Smedema ML, Connolly PA, McKinsey DS, Cloud GA, Kauffman CA, Hafner R and Wheat JL.  DNA fingerprinting of Candida isolates obtained during itraconazole prophylaxis in patients with AIDS. Medicine Mycology 2001; 39:207-213.
  6. Kauffman CA.  Fungal infections.  In:  Infectious Diseases in Aging:  A clinical handbook.  Yoshikawa TT, Norman DC (eds). Humana Press, Totowa, NJ 2001:211-224.

2002 

  1. Walsh TJ, Pappas P, Winston D, Blumer J, Finn P, Raffalli J, Yanovich S, Stiff P, Greenberg R, Donowitz G, Lee J, Schuster M, Reboli A, Wingard J, Arndt C, Reinhardt J, Hadley S, Finberg R, Laverdiere M, Perfect J, Garber G, Fioritoni G, Anaissie E and for the NIAID Mycoses Study Group.  Voriconazole versus liposomal amphotericin B for empirical antifungal therapy in persistently febrile neutropenic patients:  a prospective, randomized, multicenter, international trial.  N Engl J Med. 2002; 346:225-334.
  2. Johnson PC, Wheat LJ, Cloud GA, Goldman M, Lancaster D, Bamberger DM, Powderly WG, Hafner R, Kauffman CA, Dismukes WE and the NIAID Mycoses Study Group.  Safety and efficacy of liposomal amphotericin B compared with conventional amphotericin B for induction therapy of histoplasmosis in patients with AIDS. Ann Intern Med. 2002:137:105-109.

2003

1.  Rex JH, Pappas PG, Karchmer AW, Sobel J, Edwards JR, Hadley S, Brass C, Vazquez JA, Chapman SW, Horowitz H, Zervos M, Lee J and the NIAID Mycoses   Study Group.  A randomized and blinded multicenter trial of high-dose fluconazole plus placebo versus fluconazole plus amphotericin B as therapy of candidemia  and its consequences in non-neutropenic patients.   Clinical Infect Dis. 2003;   36:1221-8.

2. Pappas PG, Rex, JH, Le, J, Hamill RH, Larsen RA, Powderly W, Kauffrman C,    Hyslop N, Mangino J, Chapman S, Horowitz H, Edwards JE, Dismukes WA, and             NIAID Mycoses Study Group.   A Prospective Observational Study of Candidermia:   Epidemiology, Therapy, and Influences on Mortality in Hospitalized Adult and         Pediatrics Patients.   Clinical Infect Dis. 2003;37:634-643.

3. Van Burik JH, Ratanathathorm V, Lipton J, Miller CB, Bunin B, Walsh TJ.  Micafungin versus Fluconazole for Prophylaxis of Invasive Fungal Infections During Neutropenia in Patients Undergoing Hematopoietic Stem Cell Transplantation.  CID 2004;39:1407-16.

4.  Ostrosky-Zeichner L, Marr KA,  Rex JH, Cohen SH.   Amphotericin B:  time for a new “gold  standard”.  CID 2003;37(3):415-25.

2005

1. Larsen RA, Pappas PG, Perfect, J, Aberg, JA, Casadevall A, Cloud GA, James R,          Filler S, Dismukes WE, and the National Institute of Allergy and Infectious Diseases Mycoses Study Group. A phase I evaluation of the safety and pharmacodynamic activity of a murine derived anti-cryptococcal antibody 18B7 in subjects with treated cryptococcal meningitis.  Antimicrobial Agents and Chemotherapy 2005;49:001-007

2. Goldman M, Cloud GA, Wade KD, Reboli A, Fichtenbaum CJ, Hafner R, Sobel JD, Powderly WG, Patterson TF, Wheat LJ, Stein DK, Dismukes, WE, Filler SG.  A randomized study of the use of fluconazole as continuous versus episodic therapy in patients with advanced HIV infection and history of oropharyngeal candidiasis  AIDS Clinical Trials Group Study 323/ Mycoses Study Group Study 40.  CID 2005; 41:1473-80.

2006

1. Pappas PG, Andes D, Schuster M, Hadley S, Rabkin J, Merion RM, Kauffman CA,  Huckabee C, Cloud GA, Dismukes WE, Karchmer AW.  Invasive fungal         infections in low risk liver transplant recipients:  A multicenter prospective observational study.  American Journal of Transplantation 2006;  6: 386-391.

 


           
 
(412) 343-2437
headquarters@msgerc.org

MSGERC Privacy Policy   

Powered by Wild Apricot Membership Software